TGFB1 and neoplasm: Elevated cytokines (IL-22, IL-6) in plasma and tumor tissue are associated with resistance to EGFR-TKI therapy.Targeting cytokines (IL-6, IL-8, TGF-β) combined with EGFR-TKIs may help overcome resistance in NSCLC.